Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.

@article{Gravina2013IncreasedLO,
  title={Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.},
  author={Giovanni Luca Gravina and Guido Ranieri and Paola Muzi and Francesco Marampon and Andrea Mancini and Boris Di Pasquale and Luigi Di Clemente and Vincenza Dolo and Anna Maria D'Alessandro and Claudio Festuccia},
  journal={Oncology reports},
  year={2013},
  volume={29 3},
  pages={
          1189-95
        }
}
DNA methylation might be the earliest somatic genome changes in prostate cancer that also play an important role in the process of tumor invasion, growth and metastasis. In recent years, several inhibitors of DNA methyltransferases (DNMTis) have been developed and evaluated in pre-clinical models and in clinical trials. While these compounds are effective in the treatment of hematological conditions, clinical trials in solid tumors and… Expand
Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression.
TLDR
The results showed that DNMT1 and DNMT3L were upregulated early in prostate cancer progression, whereas DNMT2 was upregulated as a response to androgen ablation, andDNMT3B were higher in the late stages of prostate cancer progress, i.e., the emergence of castrate resistance and androgen-independent growth. Expand
Expression of 5‐methylcytosine regulators is highly associated with the clinical phenotypes of prostate cancer and DNMTs expression predicts biochemical recurrence
TLDR
The results show that DNA methyltransferases (DNMTs) are strongly associated with pathologic phenotypes and immune infiltration patterns in PCa and a two-factor predictive model using the expression features of DNMT3B and DNMT1 was built to predict the BCR status of patients with PCa. Expand
The role of TET-mediated DNA hydroxymethylation in prostate cancer
TLDR
Recent advances in the current understanding of how TET expression and function are regulated in development and cancer are explored and the impact on 5hmC in prostate cancer and the potential underlying mechanisms are looked at. Expand
Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression.
  • M. Li, Y. Wang, +5 authors B. Wu
  • Biology, Medicine
  • Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
  • 2014
TLDR
Experiments in vitro showed DNMT1 played an essential role in proliferation and invasion of renal cancer cells, and targeting this enzyme could be a promising strategy for treating ccRCC, as evidenced by inhibited cell viability, increased apoptosis, decreased colony formation and invading ability. Expand
Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention
TLDR
The present status of epigenetic biomarkers and their clinical impacts on prostate cancer are described and the role of different epigenetic master regulators involved in the management of disease, appropriate treatment landscape, and the recent preclinical and ongoing clinical evaluations are deliberated. Expand
Epigenetic mechanisms underlying prostate cancer radioresistance
TLDR
This review summarizes the major epigenetically induced changes in radioresistant-like PCa cells and describes recently reported targeted epigenetic therapies in pre-clinical and clinical settings. Expand
Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth
TLDR
A tumor suppressor role for nc886 in the prostate, whose expression is epigenetically silenced in cancer leading to an increase in cell proliferation and invasion is suggested. Expand
Exploiting Epigenetic Alterations in Prostate Cancer
TLDR
In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. Expand
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
TLDR
It is found that altering the balance between histone methylation and demethylation impacted growth and proliferation, and KDM3B, a histone H3K9 demethylase, was found to have the most antiproliferative effect. Expand
Prostate cancer invasion and metastasis: insights from mining genomic data.
TLDR
Novel biomarkers are strongly needed to enable more accurate detection of PCa, improve prediction of tumor aggressiveness and facilitate the discovery of new therapeutic targets for tailored medicine. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
The emerging roles of DNA methylation in the clinical management of prostate cancer.
TLDR
The major developments in the fields of prostate cancer and DNA methylation are discussed, and how this epigenetic modification can be harnessed to address some of the key issues impeding the successful clinical management of Prostate cancer. Expand
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
TLDR
The present article will provide a brief review of the biological significance and rationale for the clinical potential of DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation, and the molecular basis and mechanisms of action for these combined treatments will be discussed herein. Expand
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer.
TLDR
The data suggests that antiandrogenic therapy reducedPTEN expression by epigenetic mechanisms suggesting that epigenetic drugs, upmodulating PTEN expression, can reduce Akt activity and probably enhance the efficacy of antiandrogensic therapy. Expand
Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
TLDR
Differential expression of epithelial and prostatic markers in 30 PCa-, 6 high grade prostate intraepithelial neoplasia (PIN)- and 6 BPH-derived primary cell cultures is shown. Expand
A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma.
TLDR
The findings suggest that the combination treatment with Aza and VBL is effective against RCC, and the cytotoxicity of VBL was enhanced in vitro in three RCC cell lines by Aza treatment. Expand
GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer Cells
TLDR
It is shown that GSTP1 DNA methylation and protein expression status is correlated with DNMTi treatment response in prostate cancer cells and these results warrant its testing as a marker of epigenetic therapy response in future clinical trials. Expand
Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
TLDR
Changes in the DNA methylation machinery are associated with resistance to docetaxel in breast cancer cells, and the use of epigenetic therapies, as a strategy to overcome drug resistance, needs to be investigated more fully to determine their effectiveness in different cancers and for different chemotherapy drugs. Expand
VCaP, a cell-based model system of human prostate cancer.
TLDR
This cell line was derived from a metastatic tumor to the vertebrae of a prostate cancer patient and exhibits many of the characteristics of clinical prostate carcinoma, including expression of PSA, PAP, and AR. Expand
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.
TLDR
Evidence of a relationship between the castration-resistant phenotype and DNMT expression and activity in human prostate cancer is provided, as small interfering RNA treatment targeting the androgen receptor greatly decreased the modulation of DNMT activity under androgenic and antiandrogenic stimulation. Expand
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
TLDR
The results provide a rationale for clinical trials on combination treatments with azacitidine in patients with hormone-refractory and chemoresistant prostate tumors and show synergistic effects with both DTX and cisplatin. Expand
...
1
2
3
4
5
...